1. Abdel-Rahman, S. M., & Kauffman, R. E. (2004). The integration of pharmacokinetics and pharmacodynamics: Understanding dose-response. Annual Review of Pharmacology and Toxicology, 44, 111–136.
2. Benarroch, E. E. (2009). Neurotransmitters. In S. A. Waldman & A. Terzic (Hrsg.), Pharmacology and therapeutics: Principles to practice (S. 9–113). Philadelphia: Saunders Elsevier.
3. Blumenthal, D. K., & Garrison, J. C. (2011). Pharmacodynamics: Molecular mechanisms of drug action. In L. Brunton, B. Chabner & B. Knollmann (Hrsg.), Goodman & Gilman’s the pharmacological basis of therapeutics (S. 42–72). New York: McGrawHill.
4. Citri, A., & Yarden, Y. (2006). EGF-ERBB signalling: Towards the systems level. Nature Reviews Molecular Cell Biology, 7(7), 505–516.
5. de la Torre, R., Yubero-Lahoz, S., Pardo-Lozano, R., & Farré, M. (2012). MDMA, methamphetamine, and CYP2D6 pharmacogenetics: What is clinically relevant? Frontiers in Genetics, 3, 235. doi:10.3389/fgene.2012.00235.